Hemogenyx Pharmaceuticals plc (LSE:HEMO) is pleased to announce that following the live investor webinar presented by Dr Vladislav Sandler, Chief Executive Officer and Co-Founder of Hemogenyx Pharmaceuticals held on 6 July 2022, a recording of the webinar is now available to view on the Company’s YouTube channel at https://youtu.be/LFH95Zw8e6Y
LONDON, ENGLAND / ACCESSWIRE / July 8, 2022 /HemoGenyx LLC (LSE:HEMO) is pleased to announce that following the live investor webinar presented by Dr Vladislav Sandler, Chief Executive Officer and Co-Founder of Hemogenyx Pharmaceuticals held on 6 July 2022, a recording of the webinar is now available to view on the Company’s YouTube channel at https://youtu.be/LFH95Zw8e6Y
Enquiries:
| Hemogenyx Pharmaceuticals plc | https://hemogenyx.com |
| Dr Vladislav Sandler, Chief Executive Officer & Co-Founder | headquarters@hemogenyx.com |
| Peter Redmond, Director | peter.redmond@hemogenyx.com |
| SP Angel Corporate Finance LLP | Tel: +44 (0)20 3470 0470 |
| Matthew Johnson, Vadim Alexandre, Adam Cowl | |
| Peterhouse Capital Limited | Tel: +44 (0)20 7469 0930 |
| Lucy Williams, Duncan Vasey, Charles Goodfellow | |
About Hemogenyx Pharmaceuticals plc
Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its state-of-the-art research facility.
The Company is a pre-clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune disease and to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as a platform technology that it uses as an engine for novel product development.
For more than 50 years, bone marrow transplantation has been used to save the lives of patients suffering from blood diseases. The risks of toxicity and death that are associated with bone marrow transplantation, however, have meant that the procedure is restricted to use only as a last resort. The Company’s technology has the potential to enable many more patients suffering from devastating blood diseases such as leukemia and lymphoma, as well as severe autoimmune diseases such as multiple sclerosis, aplastic anemia and systemic lupus erythematosus (Lupus), to benefit from bone marrow transplantation.
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
SOURCE: Hemogenyx Pharmaceuticals PLC
View source version on accesswire.com:
https://www.accesswire.com/707997/Hemogenyx-Pharmaceuticals-PLC-Announces-Investor-Webinar-Recording
